![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1629686
¼¼°èÀÇ ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°Cardiogenic Shock Treatment Market, By Treatment Type, By End User, By Geography |
¼¼°èÀÇ ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀåÀº 2024³â¿¡´Â 11¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, 2024³âºÎÅÍ 2031³â±îÁöÀÇ CAGRÀº 7.1%¸¦ ³ªÅ¸³»¸ç, 2031³â¿¡´Â 17¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2023³â | 2024³â ½ÃÀå ±Ô¸ð | 11¾ï ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2019-2023³â | ¿¹Ãø ±â°£ | 2024-2031³â |
¿¹Ãø±â°£ 2024-2031³â CAGR: | 7.10% | 2031³â °¡Ä¡ ¿¹Ãø | 17¾ï 8,000¸¸ ´Þ·¯ |
½É¿ø¼º ¼îÅ©´Â ½ÉÀåÀÌ °©ÀÚ±â, ½ÅüÀÇ Çʿ䷮À» ä¿ì±â¿¡ ÃæºÐÇÑ Ç÷¾×À» º¸³¾ ¼ö ¾ø°Ô µÇ´Â »ý¸íÀ» À§ÇùÇÏ´Â »óÅÂÀÔ´Ï´Ù.ÀÌ Àå¾Ö´Â ½ÉÀå ¹ßÀÛ, ½ÉÀå ¼ö¼ú ÈÄÀÇ ÇÕº´Áõ, ½É±Ù °¨¿°Áõ µî »óÅ¿¡¼ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Å¼ÓÇÏ°Ô Àå±â ±â´ÉºÎÀü¿¡ ºüÁ® Á×À½¿¡ À̸£±âµµ ÇÕ´Ï´Ù. ¼¼°èÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
¼¼°èÀÇ ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀåÀº ÁÖ·Î °ü»ó µ¿¸Æ Áúȯ, ½ÉÀå ¹ßÀÛ, ½ÉºÎÀü µîÀÇ ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀº ¼¼°èÀÇ »ç¸Á ¿øÀÎÀÇ Á¦1À§À̸ç, ¸Å³â 1,790¸¸¸í ÀÌ»óÀÇ »ý¸íÀÌ »©¾Ñ±â°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ½¬¿î ³ë³â Àα¸ Áõ°¡µµ ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù. °ú ¼ö¼ú ÀýÂ÷¿¡ µû¸¥ °í¾×ÀÇ ºñ¿ëÀº Àú¼Òµæ Áö¿ª¿¡¼ ½ÃÀå ħÅõ¸¦ ¹æÇØÇϰí ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼´Â ¼¼°èÀÇ ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2023³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð ¹× º¹ÇÕ¿¬°£ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.
¼¼°èÀÇ ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷¿¡ ´ëÇØ¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ¹ÙÅÁÀ¸·Î ÇÁ·ÎÆÄÀÏÇϰí ÀÖ½À´Ï´Ù.
ÀÌ ¿¬±¸ÀÇ ´ë»óÀ̵Ǵ ÁÖ¿ä ±â¾÷Àº Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG(part of Fresenius Medical Care), Windtree Therapeutics, Chiesi Farmaceutici SpA µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ½É¿ø¼º ¼îÅ© Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.
The global cardiogenic shock treatment market is estimated to be valued at USD 1.10 Bn in 2024 and is expected to reach USD 1.78 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 1.10 Bn |
Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: | 7.10% | 2031 Value Projection: | US$ 1.78 Bn |
Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's need. This failure can result from conditions like heart attack, complications after heart surgery, or heart muscle infection. Without prompt treatment it can rapidly lead to organ dysfunction and death. Globally rising cases of cardiovascular diseases and increasing demand for effective management of complex cardiac conditions are the major factors anticipated to boost the growth of the cardiogenic shock treatment market worldwide in the coming years.
The global cardiogenic shock treatment market is primarily driven by the increasing prevalence of cardiovascular diseases such as coronary artery disease, heart attacks, and heart failures. According to the World Health Organization, in June 2021, cardiovascular diseases are the leading cause of deaths globally, taking an estimate of over 17.9 million lives each year. Moreover, rising geriatric population susceptible to develop such critical cardiac conditions also supports the market growth. Various technological advancements in mechanical circulatory support devices and rapid adoption of these effective management options offer new opportunities. However, high cost associated with devices and surgical procedures hampers market penetration in low-income regions. Additionally, lack of awareness among people about early diagnosis and management options pose challenges.
This report provides in-depth analysis of the global cardiogenic shock treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cardiogenic shock treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global cardiogenic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiogenic shock treatment market